Financhill
Sell
50

ILMN Quote, Financials, Valuation and Earnings

Last price:
$89.57
Seasonality move :
2.38%
Day range:
$86.03 - $90.42
52-week range:
$68.70 - $156.66
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.31x
P/B ratio:
6.03x
Volume:
1.8M
Avg. volume:
2.3M
1-year change:
-14.75%
Market cap:
$14.3B
Revenue:
$4.4B
EPS (TTM):
-$6.07

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ILMN
Illumina
$1B $0.94 -5.72% 430.2% $108.48
CTSO
CytoSorbents
$9M -$0.07 10.68% -41.38% $5.00
DCTH
Delcath Systems
$16.8M $0.03 194.07% -93.78% $24.08
DHR
Danaher
$5.6B $1.64 1.5% 34.41% $247.14
EXAS
Exact Sciences
$688.6M -$0.10 10.52% -84.17% $68.86
STRR
Star Equity Holdings
$16.4M -$0.25 24.23% -43.28% $8.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ILMN
Illumina
$90.25 $108.48 $14.3B -- $0.00 0% 3.31x
CTSO
CytoSorbents
$1.22 $5.00 $76.4M -- $0.00 0% 1.93x
DCTH
Delcath Systems
$15.43 $24.08 $537.4M -- $0.00 0% 9.47x
DHR
Danaher
$201.11 $247.14 $143.9B 39.05x $0.32 0.56% 6.17x
EXAS
Exact Sciences
$53.30 $68.86 $10.1B -- $0.00 0% 3.49x
STRR
Star Equity Holdings
$1.98 $8.50 $6.4M 0.75x $0.00 0% 0.11x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ILMN
Illumina
45.66% 1.567 15.77% 1.34x
CTSO
CytoSorbents
49.38% 0.020 22.69% 1.98x
DCTH
Delcath Systems
-- 2.956 -- 13.86x
DHR
Danaher
24.47% 0.156 11.23% 0.83x
EXAS
Exact Sciences
49.21% 1.742 28.45% 2.12x
STRR
Star Equity Holdings
18.39% 0.331 40.47% 0.69x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ILMN
Illumina
$683M $164M -20.34% -34.38% 19.89% $201M
CTSO
CytoSorbents
$6.2M -$3.9M -58.93% -106.57% -10.01% -$3.5M
DCTH
Delcath Systems
$16.9M $642K -37.34% -40.28% 3.25% $2.1M
DHR
Danaher
$3.5B $1.3B 5.53% 7.38% 20.92% $1.1B
EXAS
Exact Sciences
$500.5M -$89.8M -19.08% -35.57% -13.04% -$365K
STRR
Star Equity Holdings
$3.1M -$2.8M -13.58% -15.99% -22.03% $200K

Illumina vs. Competitors

  • Which has Higher Returns ILMN or CTSO?

    CytoSorbents has a net margin of 12.58% compared to Illumina's net margin of -16.94%. Illumina's return on equity of -34.38% beat CytoSorbents's return on equity of -106.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    ILMN
    Illumina
    65.61% $0.82 $4.4B
    CTSO
    CytoSorbents
    71.13% -$0.02 $28.7M
  • What do Analysts Say About ILMN or CTSO?

    Illumina has a consensus price target of $108.48, signalling upside risk potential of 20.2%. On the other hand CytoSorbents has an analysts' consensus of $5.00 which suggests that it could grow by 309.84%. Given that CytoSorbents has higher upside potential than Illumina, analysts believe CytoSorbents is more attractive than Illumina.

    Company Buy Ratings Hold Ratings Sell Ratings
    ILMN
    Illumina
    7 10 0
    CTSO
    CytoSorbents
    1 1 0
  • Is ILMN or CTSO More Risky?

    Illumina has a beta of 1.324, which suggesting that the stock is 32.43% more volatile than S&P 500. In comparison CytoSorbents has a beta of 1.046, suggesting its more volatile than the S&P 500 by 4.577%.

  • Which is a Better Dividend Stock ILMN or CTSO?

    Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytoSorbents offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina pays -- of its earnings as a dividend. CytoSorbents pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ILMN or CTSO?

    Illumina quarterly revenues are $1B, which are larger than CytoSorbents quarterly revenues of $8.7M. Illumina's net income of $131M is higher than CytoSorbents's net income of -$1.5M. Notably, Illumina's price-to-earnings ratio is -- while CytoSorbents's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 3.31x versus 1.93x for CytoSorbents. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ILMN
    Illumina
    3.31x -- $1B $131M
    CTSO
    CytoSorbents
    1.93x -- $8.7M -$1.5M
  • Which has Higher Returns ILMN or DCTH?

    Delcath Systems has a net margin of 12.58% compared to Illumina's net margin of 5.4%. Illumina's return on equity of -34.38% beat Delcath Systems's return on equity of -40.28%.

    Company Gross Margin Earnings Per Share Invested Capital
    ILMN
    Illumina
    65.61% $0.82 $4.4B
    DCTH
    Delcath Systems
    85.62% $0.03 $80.2M
  • What do Analysts Say About ILMN or DCTH?

    Illumina has a consensus price target of $108.48, signalling upside risk potential of 20.2%. On the other hand Delcath Systems has an analysts' consensus of $24.08 which suggests that it could grow by 56.05%. Given that Delcath Systems has higher upside potential than Illumina, analysts believe Delcath Systems is more attractive than Illumina.

    Company Buy Ratings Hold Ratings Sell Ratings
    ILMN
    Illumina
    7 10 0
    DCTH
    Delcath Systems
    4 0 0
  • Is ILMN or DCTH More Risky?

    Illumina has a beta of 1.324, which suggesting that the stock is 32.43% more volatile than S&P 500. In comparison Delcath Systems has a beta of 0.948, suggesting its less volatile than the S&P 500 by 5.238%.

  • Which is a Better Dividend Stock ILMN or DCTH?

    Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ILMN or DCTH?

    Illumina quarterly revenues are $1B, which are larger than Delcath Systems quarterly revenues of $19.8M. Illumina's net income of $131M is higher than Delcath Systems's net income of $1.1M. Notably, Illumina's price-to-earnings ratio is -- while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 3.31x versus 9.47x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ILMN
    Illumina
    3.31x -- $1B $131M
    DCTH
    Delcath Systems
    9.47x -- $19.8M $1.1M
  • Which has Higher Returns ILMN or DHR?

    Danaher has a net margin of 12.58% compared to Illumina's net margin of 16.62%. Illumina's return on equity of -34.38% beat Danaher's return on equity of 7.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    ILMN
    Illumina
    65.61% $0.82 $4.4B
    DHR
    Danaher
    61.16% $1.32 $67.3B
  • What do Analysts Say About ILMN or DHR?

    Illumina has a consensus price target of $108.48, signalling upside risk potential of 20.2%. On the other hand Danaher has an analysts' consensus of $247.14 which suggests that it could grow by 22.89%. Given that Danaher has higher upside potential than Illumina, analysts believe Danaher is more attractive than Illumina.

    Company Buy Ratings Hold Ratings Sell Ratings
    ILMN
    Illumina
    7 10 0
    DHR
    Danaher
    19 3 0
  • Is ILMN or DHR More Risky?

    Illumina has a beta of 1.324, which suggesting that the stock is 32.43% more volatile than S&P 500. In comparison Danaher has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.765%.

  • Which is a Better Dividend Stock ILMN or DHR?

    Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Danaher offers a yield of 0.56% to investors and pays a quarterly dividend of $0.32 per share. Illumina pays -- of its earnings as a dividend. Danaher pays out 19.7% of its earnings as a dividend. Danaher's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ILMN or DHR?

    Illumina quarterly revenues are $1B, which are smaller than Danaher quarterly revenues of $5.7B. Illumina's net income of $131M is lower than Danaher's net income of $954M. Notably, Illumina's price-to-earnings ratio is -- while Danaher's PE ratio is 39.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 3.31x versus 6.17x for Danaher. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ILMN
    Illumina
    3.31x -- $1B $131M
    DHR
    Danaher
    6.17x 39.05x $5.7B $954M
  • Which has Higher Returns ILMN or EXAS?

    Exact Sciences has a net margin of 12.58% compared to Illumina's net margin of -14.32%. Illumina's return on equity of -34.38% beat Exact Sciences's return on equity of -35.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    ILMN
    Illumina
    65.61% $0.82 $4.4B
    EXAS
    Exact Sciences
    70.82% -$0.54 $4.7B
  • What do Analysts Say About ILMN or EXAS?

    Illumina has a consensus price target of $108.48, signalling upside risk potential of 20.2%. On the other hand Exact Sciences has an analysts' consensus of $68.86 which suggests that it could grow by 29.19%. Given that Exact Sciences has higher upside potential than Illumina, analysts believe Exact Sciences is more attractive than Illumina.

    Company Buy Ratings Hold Ratings Sell Ratings
    ILMN
    Illumina
    7 10 0
    EXAS
    Exact Sciences
    18 4 0
  • Is ILMN or EXAS More Risky?

    Illumina has a beta of 1.324, which suggesting that the stock is 32.43% more volatile than S&P 500. In comparison Exact Sciences has a beta of 0.977, suggesting its less volatile than the S&P 500 by 2.282%.

  • Which is a Better Dividend Stock ILMN or EXAS?

    Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ILMN or EXAS?

    Illumina quarterly revenues are $1B, which are larger than Exact Sciences quarterly revenues of $706.8M. Illumina's net income of $131M is higher than Exact Sciences's net income of -$101.2M. Notably, Illumina's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 3.31x versus 3.49x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ILMN
    Illumina
    3.31x -- $1B $131M
    EXAS
    Exact Sciences
    3.49x -- $706.8M -$101.2M
  • Which has Higher Returns ILMN or STRR?

    Star Equity Holdings has a net margin of 12.58% compared to Illumina's net margin of -9.1%. Illumina's return on equity of -34.38% beat Star Equity Holdings's return on equity of -15.99%.

    Company Gross Margin Earnings Per Share Invested Capital
    ILMN
    Illumina
    65.61% $0.82 $4.4B
    STRR
    Star Equity Holdings
    24.27% -$0.52 $73.2M
  • What do Analysts Say About ILMN or STRR?

    Illumina has a consensus price target of $108.48, signalling upside risk potential of 20.2%. On the other hand Star Equity Holdings has an analysts' consensus of $8.50 which suggests that it could grow by 329.29%. Given that Star Equity Holdings has higher upside potential than Illumina, analysts believe Star Equity Holdings is more attractive than Illumina.

    Company Buy Ratings Hold Ratings Sell Ratings
    ILMN
    Illumina
    7 10 0
    STRR
    Star Equity Holdings
    1 0 0
  • Is ILMN or STRR More Risky?

    Illumina has a beta of 1.324, which suggesting that the stock is 32.43% more volatile than S&P 500. In comparison Star Equity Holdings has a beta of 1.002, suggesting its more volatile than the S&P 500 by 0.203%.

  • Which is a Better Dividend Stock ILMN or STRR?

    Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.

  • Which has Better Financial Ratios ILMN or STRR?

    Illumina quarterly revenues are $1B, which are larger than Star Equity Holdings quarterly revenues of $12.9M. Illumina's net income of $131M is higher than Star Equity Holdings's net income of -$1.2M. Notably, Illumina's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 3.31x versus 0.11x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ILMN
    Illumina
    3.31x -- $1B $131M
    STRR
    Star Equity Holdings
    0.11x 0.75x $12.9M -$1.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Reddit Stock Be In 5 Years?
Where Will Reddit Stock Be In 5 Years?

On a wet March morning last year, the famously orange…

Will Palantir Crash?
Will Palantir Crash?

AI and data analytics software major Palantir (NASDAQ:PLTR) has been…

Is Target’s Dividend Worth Buying?
Is Target’s Dividend Worth Buying?

Retail giant Target (NYSE:TGT) has been through an extremely volatile…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 41x

Buy
60
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 49x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
49
RGC alert for Jun 17

Regencell Bioscience Holdings [RGC] is up 30.47% over the past day.

Buy
79
ARQQ alert for Jun 18

Arqit Quantum [ARQQ] is up 6.36% over the past day.

Buy
59
SYM alert for Jun 17

Symbotic [SYM] is down 3.91% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock